Synthesis, Characterization and Evaluation of Topical Antiinflammatory Activity of Dimethyl 4-Oxo-2,6-diphenylcyclohexane-1,1-dicarboxylate

MAZIN NADHIM MOUSA AL UGLA

Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, University of Basrah, Basrah, Iraq

Corresponding author: E-mail: malugla@yahoo.com

(Received: 4 November 2011;

Accepted: 5 November 2012)

AJC-12361

An attempt was made to synthesize a topical preparation of an active compound that has a potent antiinflammatory activity. Dimethyl 4-oxo-2,6-diphenylcyclohexane-1,1-dicarboxylate (**II**) was prepared by aldol condensation of benzaldehyde and acetone followed by Michael addition of dimethyl malonate. The optimum concentration of the compound was determined by comparing the antiinflammatory effect of ointment preparations at different concentrations. The antiinflammatory effects were studied by using carrageenan-induced paw edema method in rat and xylene induced rat ear edema. Good effect was observed with ointment containing 4 % and 5 % of the compound **II** concentration. The results showed that the drug had an obvious antiinflammatory effect as an external preparation and the activity is comparable to that of the standard ointment.

Key Words: Antiinflammatory, Carrageenan-induced edema, Xylene induced edema.

INTRODUCTION

Inflammation is a localized protective response characterized by injury or destruction of tissues, which serve to destroy, dilute or sequester both the injurious agent and injured tissue.

Antiinflammatory agents are used in the treatment of inflammation. There are two main types of antiinflammatory agents; glucocorticosteroids and non-steroidal antiinflammatory drugs. The non-steroidal antiinflammatory drugs is so named because they do not belong to the steroidal groups and ceases discomfort by blocking the pathway of cyclo-oxygenase enzyme that creates prostaglandins and lessen the pain in different parts of the body. While the steroids reduces the inflammation by binding to cortisol receptors.

Many therapeutic agents from synthetic source have advantages and disadvantages, which limits their usefulness on long term basis. Similarly, non-steroidal antiinflammatory drugs also show many side effects includes stomach ulcers, bleeding ulcers, kidney dysfunction, constipation, dizziness and headaches¹. Thus, the application of the drug on the affected site or the nearby area is reasonable, since drugs produce effects after they reach the affected site. Topical non-steroidal anti inflammatory drugs are applied on the skin in the form of ointment, gel, cream or spray in the region where pain is exist². They have to penetrate the skin, enter tissues or joints and at high concentration to have an effect on the

inflammation process causing pain. The inhibitory activities of non-steroidal antiinflammatory drug ointment on inflammatory responses were almost the same as those obtained by oral administration of such non-steroidal antiinflammatory drug and more potent than those of steroidal ointment³. So, the aim of this study is to develop a compound that have antiinflammatory effect, applied topically to reduce the side effects.

EXPERIMENTAL

Synthesis of (1E, 4E)-1,5-diphenylpenta-1,4-dien-3-one (I): In a 100 mL beaker, place 10 mL of 3 M sodium hydroxide solution, 16 mL of 95 % ethanol and 2.12 g (20 mmol) of benzaldehyde, then add 0.58 g (10 mmol) of acetone to the reaction mixture and shake the mixture. The benzaldehyde, initially insoluble, goes into solution, resulting in a clear, pale-yellow solution. After a minute it suddenly becomes cloudy and a yellow precipitate product forms. Continue to shake the beaker for the next 10 min. Remove the liquid from the beaker and add 30 mL of water and shake it vigorously. Remove the wash liquid and wash the crystals twice with 20-mL portions of water and then filtration by vacuum, drying and recrystallized from hot ethanol. The yield was *ca.* 78 % and the melting point was 111-112 °C.⁴

IR (KBr, $\nu_{\max}$, cm^{-1}): 3051.1 (Ar. C-H stretching), 3029.9 (C-H stretching), 1649 (C=O stretching), 1591, 1496 (Ar. C=C stretching), 883 (Ar. C-H out of plane).

TABLE-2
EFFECT OF TOPICAL APPLICATION OF THE FORMULATION ON CARRAGEENAN INDUCED PAW EDEMA IN RATS

Compound	Change in paw volume (in mL) after drug administration (Mean $\pm$ SEM)				Percentage inhibition of edema			
	1 h	2 h	3 h	4h	1 h	2 h	3 h	4h
Control	0.71 $\pm$ 0.02	0.77 $\pm$ 0.02	0.71 $\pm$ 0.02	0.60 $\pm$ 0.02	-	-	-	-
Standard	0.42 $\pm$ 0.03**	0.43 $\pm$ 0.04**	0.44 $\pm$ 0.04**	0.40 $\pm$ 0.03**	40	44	38	33
F1	0.58 $\pm$ 0.04	0.60 $\pm$ 0.01	0.57 $\pm$ 0.05	0.49 $\pm$ 0.03	19	22	21	19
F2	0.54 $\pm$ 0.02*	0.57 $\pm$ 0.01*	0.53 $\pm$ 0.04	0.48 $\pm$ 0.04	24	26	26	20
F3	0.52 $\pm$ 0.01*	0.55 $\pm$ 0.01*	0.51 $\pm$ 0.04*	0.48 $\pm$ 0.04	27	28	29	20
F4	0.49 $\pm$ 0.02**	0.53 $\pm$ 0.02**	0.48 $\pm$ 0.04**	0.47 $\pm$ 0.04	30	31	33	22
F5	0.47 $\pm$ 0.04**	0.50 $\pm$ 0.04**	0.47 $\pm$ 0.04**	0.46 $\pm$ 0.04	34	35	34	24

SEM- Standard error mean, *P < 0.05; **P < 0.01

Synthesis of dimethyl 4-oxo-2,6-diphenylcyclohexane-1,1-dicarboxylate (II): Dissolve 1 g (4.46 mmol) of compound I in methanol, to which add dimethyl malonate 0.6 g (4.5 mmol) and 3 mL 25 % sodium hydroxide solution and reflux for 5 min, then left for it over night, cool and collect the product by vacuum filtration and recrystallized from ethanol and water. The yield was about 81 % and the melting point was 292-295 °C.

IR (KBr, $\nu_{\max}$ cm^{-1}): 3047 (Ar. C-H stretching), 2873 (C-H stretching CH_3), 2851 (C-H stretching CH_2) 1735 (ester C=O), 1672 (keton C=O), 1587, 1501 (Ar. C=C stretching), 1370 (C-H bending CH_3), 1105 (C-O stretching), 879 (Ar. C-H out of plane).

$^1\text{H NMR}$ (DMSO): δ 7.39 (4H), δ 7.31 (4H), δ 7.26 (2H), δ 4.34 (2H), δ 3.66 (6H), δ 2.61 (4H), $\text{C}_{22}\text{H}_{22}\text{O}_5$ (m.w. 366): Elemental analysis (%) (Calcd.) C, 72.12; H, 6.05; (Found) C, 72.3; H, 6.09.

Method of preparation of ointment⁵: Ointment was prepared by melting together petrolatum, polyethylene glycol-3000, propylene glycol and menthol on a hot plate (70 °C). The compound II was dissolved in it under stirring and cooled. Various compositions of ointment formulations were mentioned in the Table-1.

Antiinflammatory activity

Carrageenan-induced rat paw edema: Antiinflammatory activity was carried out using carrageenan-induced rat paw edema⁶. The rats weighing between 150-200 g were selected randomly excluding pregnant female rats for the test. Animals were divided into different groups with six animals in each group. One group of rats were treated with ointment base which served as control, other group was treated with standard oint-

ment (0.1 % diclofenac sodium in ointment base). Remaining groups were treated with formulated ointment (F1-F5). 0.2 g of ointment was applied to the plantar surface of the hind paw by gentle rubbing 50 times with index finger. After 30 min, 0.1 mL of 1 % w/v of carrageenan was injected in the plantar region of the left paw of rats. The paw volumes were noted for 1, 2, 3 and 4 h after carrageenan injection. The results were tabulated in Table-2. The percentage edema inhibition by the drug was calculated by the formula:

Percentage edema inhibition = $[1 - (V_t / V_c)] \times 100 \%$
where, V_t is edema volume in drug treated group. V_c is edema volume in the control group.

TABLE-1
COMPOSITION USED IN THE STUDY
TO PREPARE THE OINTMENTS

Ingredients (g)	F1	F2	F3	F4	F5
Tested compound	0.1	0.2	0.3	0.4	0.5
Polyethyleneglycol-3000	0.6	0.6	0.6	0.6	0.6
Propylene glycol	0.4	0.4	0.4	0.4	0.4
Menthol	0.5	0.5	0.5	0.5	0.5
Petroleum	q.s. to 10	q.s. to 10	q.s. to 10	q.s. to 10	q.s. to 10

SEM-Standard error mean, *P < 0.05; **P < 0.01

Xylene induced rat ear edema: The effect of the product on acute edema was assessed by using xylene induced ear edema in rats as described by Dkhil *et al.*⁷. The animals were divided into six groups each of six animals. 50 μL of xylene was applied to the anterior and posterior surfaces of the two ears under light ether anesthesia. After 15 mins, 0.1 g of the formulated ointment (F1-F5) were applied on the right ears of five groups, the sixth group receive 0.1 g diclofenac sodium

(standard). The left ear was considered as control and receive ointment base only. After 4 h, xylene application rats were sacrificed and both ears were removed. Ear lobes were punched out in circular disc using metal punch (6 mm diameter) and weighed. The difference in the weight of discs from right treated and left untreated was calculated and was used as measure of edema. The results were tabulated in Table- 3. The level of percentage inhibition was calculated using the formula: Percentage inhibition (%) = [(control-treated)/control] × 100%

Statistical analysis: The results were expressed in mean ± SEM. The data from experiments were analyzed separately using one-way Anova followed by Dunnett test was used to determine significant difference between the groups and $p < 0.05$ was considered significant.

TABLE-3
EFFECT OF TOPICAL APPLICATION OF THE FORMULATION
ON XYLENE INDUCED RATS EAR EDMA MODEL

Treatment groups	Ear edema (mg) (Mean ± SEM)	Inhibition (%)
Control	8.33 ± 0.61	-
Standard	3.50 ± 0.22	57.98
F1	7.31 ± 0.55	12.2
F2	6.52 ± 0.32	21.7*
F3	5.47 ± 0.37	34.3*
F4	4.13 ± 0.28	50.4**
F5	3.95 ± 0.23	52.6**

SEM- Standard error mean, * $P < 0.05$; ** $P < 0.01$

RESULTS AND DISCUSSION

Statistical analysis showed that, the edema inhibition was significantly different from control group at all the tested concentrations. The results showed that the antiinflammatory effect was more for the formulations containing 4 % and 5 % of the tested compound.

Different formulations (F1-F5) were prepared by keeping the ointment base constant and changing the drug ratio (1-5 %). All the formulations were stable for evaluation of anti-inflammatory activity.

Antiinflammatory activity was carried out for the formulated compounds using carrageenan-induced rat paw edema method and xylene induced rat ear edema.

Carrageenan-induced paw edema in rat and xylene induced rat ear edema has been accepted as a useful phlogistic tool for investigating antiinflammatory agents. It is suggested that there are biphasic effects in carrageenan-induced edema. The early hyperemia results from the release of histamine and serotonin, the delayed phase of carrageenan-induced edema results mainly from the potentiating effects of bradykinin on mediator release and also from prostaglandins which produce edema after the mobilization of leukocytes⁸.

The edema was reached its highest thickness 4 h after the application of the stimulus⁹.

The compound II promoted a significant and dose-dependent inhibition of xylene induced skin inflammation. Topically applied xylene resulted in activation of pro-inflammatory mediators that promoted the manifestation of several inflammatory parameters similar to some skin disorders¹⁰. Using this model, compounds that inhibit this process can be target in the search for new therapeutic strategies.

Conclusion

From this result, it is concluded that topical preparation containing 5 % possesses good antiinflammatory activity which can be used for the treatment of topical inflammation.

REFERENCES

1. International Journal of PharmTech Research, Evaluation of Antiinflammatory Activity and Potency of Herbal Formulation Consists of Different Proportions of *Curcuma longa* and *Boswellia serrata* by Using Cotton Pellet granuloma and Xylene Induced Mice Ear Edema Model, vol. 2, no.3, pp. 1855-1860, July-Sept (2010).
2. K. Kyuki, *Nippon Yakurigaku Zasshi*, **79**, 461 (1982).
3. J.H. Vaile and P. Davis, *Drugs*, **56**, 783 (1998).
4. S. Handayani and I.S. Arty, *J. Phys. Sci.*, **19**, 61 (2008).
5. D. Giles, R. Karkib, F.R. Sheeba, D.P. Venkatesh and P.M. Gurubasavarajawamy, *J. Pharm. Sci. Res.*, **3**, 1253 (2011).
6. K. Morteza-Semnani, M. Saeedi and M. Hamidian, *Fitoterapia*, **75**, 123 (2004).
7. M.A. Dkhil, A.S. Abdel-Baki, S. Al-Quraishi and M. Al-Khalifa, *Afr. J. Pharm. Pharmacol.*, **4**, 115 (2010).
8. P. Garcia-Pastor, A. Randazzo, L. Gomez-Paloma, M.J. Alcaraz and M. Paya, *J. Pharmacol. Exp. Ther.*, **289**, 166 (1999).
9. F. Sharififar, P. Khazaeli and N. Alli, *Iran. J. Pharm. Sci.*, **5**, 157 (2009).
10. M. Gabor, *Methods Mol. Biol.*, **225**, 129 (2003).